Trial Profile
A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Apr 2012 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.